The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients

被引:86
作者
Cano, Stefan J. [1 ]
Lamping, Donna L. [2 ]
Bamber, Luke [3 ]
Smith, Sarah [2 ]
机构
[1] Peninsula Coll Med & Dent, Dept Clin Neurosci, Plymouth PL6 8BX, Devon, England
[2] Univ London London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1E 7HT, England
[3] Bayer Pharma AG, Wuppertal, Germany
关键词
PRO instruments; Rating scales; Reliability; Validity; Venous thromboembolism; TREATMENT SATISFACTION; OUTCOME MEASURE; EFFECT SIZES; QUALITY; RASCH; RESPONSIVENESS; QUESTIONNAIRE; SYMPTOMS; EVALUATE; SCORE;
D O I
10.1186/1477-7525-10-120
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The Anti-Clot Treatment Scale (ACTS) is a 15-item patient-reported instrument of satisfaction with anticoagulant treatment. It includes a 12-item ACTS Burdens scale and a 3-item ACTS Benefits scale. Its role in clinical trials and other settings should be supported by evidence that it is both clinically meaningful and scientifically sound. The aim of the study was to evaluate the measurement performance of the ACTS (Dutch, Italian, French, German and English language versions) in patients with venous thromboembolism based on traditional psychometric methods. Methods: ACTS Burdens and Benefits scale data from a large clinical trial (EINSTEIN DVT) involving 1336 people with venous thromboembolism were analysed at both the scale and item level. Five key psychometric properties were examined using traditional psychometric methods: acceptability, scaling assumptions, reliability (including internal consistency reliability, test-retest reproducibility); validity (including known groups and discriminant validity); and responsiveness. These methods of examination underpin the US Food and Drug Administration recommendations for patient-reported outcome instrument evaluation. Results: Overall, the 12-item ACTS Burdens scale and 3-item ACTS Benefits scale met the psychometric criteria evaluated at both item and scale levels, with the exception of some relatively minor issues in the Dutch language version, which were just below reliability criteria (i.e. alpha = 0.72, test-retest intraclass correlation = 0.79). A consistent finding from item-level evaluations of aggregate endorsement frequencies and skewness suggested that response scales may be improved by reducing the number of response options from five to four. Conclusions: Both the ACTS Burdens and ACTS Benefits scales consistently satisfied traditional reliability and validity criteria across multiple language datasets, supporting it as a clinically useful patient-reported instrument of satisfaction with anticoagulant treatment in clinical trials.
引用
收藏
页数:11
相关论文
共 45 条
  • [1] Aaronson N, 2002, QUAL LIFE RES, V11, P193
  • [2] Andrich D, 2011, EXPERT REV PHARM OUT, V11, P571, DOI [10.1586/ERP.11.59, 10.1586/erp.11.59]
  • [3] Pharmacology and management of the vitamin K antagonists
    Ansell, Jack
    Hirsh, Jack
    Hylek, Elaine
    Jacobson, Alan
    Crowther, Mark
    Palareti, Gualtiero
    [J]. CHEST, 2008, 133 (06) : 160S - 198S
  • [4] Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers
    Atkinson, MJ
    Kumar, R
    Cappelleri, JC
    Hass, SL
    [J]. VALUE IN HEALTH, 2005, 8 : S9 - S24
  • [5] Bamber L, 2011, J THROMB HAEMOST, V9, P859
  • [6] Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
    Bauersachs, Rupert
    Berkowitz, Scott D.
    Brenner, Benjamin
    Buller, Harry R.
    Decousus, Herve
    Gallus, Alex S.
    Lensing, Anthonie W.
    Misselwitz, Frank
    Prins, Martin H.
    Raskob, Gary E.
    Segers, Annelise
    Verhamme, Peter
    Wells, Phil
    Agnelli, Giancarlo
    Bounameaux, Henri
    Cohen, Alexander
    Davidson, Bruce L.
    Piovella, Franco
    Schellong, Sebastian
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) : 2499 - 2510
  • [7] BROOK RH, 1979, MED CARE, V17, P1
  • [8] Exploring disability rating scale responsiveness II: Do more response options help?
    Cano, S. J.
    O'Connor, R. J.
    Thompson, A. J.
    Hobart, J. C.
    [J]. NEUROLOGY, 2006, 67 (11) : 2056 - 2059
  • [9] Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis
    Cano, S. J.
    Barrett, L. E.
    Zajicek, J. P.
    Hobart, J. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 214 - 222
  • [10] The patient outcomes of surgery-hand/arm (POS-Hand/Arm): A new patient-based outcome measure
    Cano, SJ
    Browne, JP
    Lamping, DL
    Roberts, AHN
    McGrouther, DA
    Black, NA
    [J]. JOURNAL OF HAND SURGERY-BRITISH AND EUROPEAN VOLUME, 2004, 29B (05) : 477 - 485